(2026). Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study). Clinical Ophthalmology.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study)."
Clinical Ophthalmology 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Treatment-Naïve Diabetic Macular Edema (BIOS-DME Study)."
Clinical Ophthalmology, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.